Edasalonexent is an investigational drug being developed by Catabasis Pharmaceuticals. It is a novel NF-κB inhibitor taken via an oral route of administration.  Edasalonexent's efficacy is currently being explored in indications of Duchenne Muscular Dystrophy. The data for the phase III pivotal trial of edasalonexent, titled "POLARISDMD", which includes 131 participants is set to be released in the fourth quarter of 2020.
This article "Edasalonexent" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.